Suppr超能文献

伽玛刀手术(GKS)治疗垂体腺瘤后与垂体功能相关的剂量学因素。

Dosimetric factors associated with pituitary function after Gamma Knife Surgery (GKS) of pituitary adenomas.

机构信息

Medical Physics Department, San Raffaele Scientific Institute, Milan, Italy.

出版信息

Radiother Oncol. 2012 Jul;104(1):119-24. doi: 10.1016/j.radonc.2012.03.021. Epub 2012 May 29.

Abstract

BACKGROUND AND PURPOSE

Gamma Knife Surgery (GKS) can be an adjunctive option to surgery in the case of pituitary adenomas. The effect of dosimetric variables on the incidence of new anterior pituitary deficits after GKS requires better definition.

MATERIALS AND METHODS

This retrospective study considered 130 patients with a follow up after GKS >6 months. The diagnosis was nonfunctioning pituitary adenoma (NFPA) in 68 patients and secreting pituitary adenoma (SPA) in 62 patients. Median margin dose was 15/25 Gy for NFPA and SPA, respectively. The endocrinological median follow-up was 60 months. Hypopituitarism was defined as a new pituitary deficit in (at least) one of the three hormonal axes (hypogonadism, hypothyroidism and hypoadrenalism). The predictive value of clinical/dosimetric parameters was tested by univariate/multivariate analyses.

RESULTS

Sixteen patients (12.3%) showed a new pituitary deficit in one or more axes. Multivariate analysis confirmed that the mean dose to the stalk/pituitary and the amount of healthy tissue within the high dose region were strong independent predictors of pituitary dysfunction; their best cut-off values were around 15.7 Gy, 7.3 Gy and 1.4 cm(3), respectively.

CONCLUSIONS

Our data showed a dose-dependent incidence of new hormonal deficits after GKS for pituitary adenoma. During planning definition, the risk of hypopituitarism could be reduced using the outlined safe dose-volume values.

摘要

背景与目的

伽玛刀手术(GKS)可以作为手术治疗垂体腺瘤的辅助选择。剂量学变量对 GKS 后新发垂体前叶功能减退症发生率的影响需要更好地定义。

材料与方法

本回顾性研究纳入了 130 例 GKS 后随访时间>6 个月的患者。诊断为无功能垂体腺瘤(NFPA)的患者 68 例,分泌性垂体腺瘤(SPA)的患者 62 例。NFPA 和 SPA 的中位边缘剂量分别为 15/25 Gy。内分泌学中位随访时间为 60 个月。垂体功能减退症定义为至少一个三个激素轴(性腺功能减退、甲状腺功能减退和肾上腺功能减退)中的新的垂体功能减退。通过单变量/多变量分析测试临床/剂量学参数的预测价值。

结果

16 例(12.3%)患者在一个或多个轴上出现新的垂体功能减退。多变量分析证实,对柄/垂体的平均剂量和高剂量区域内的健康组织量是垂体功能障碍的强烈独立预测因子;其最佳截断值分别约为 15.7 Gy、7.3 Gy 和 1.4 cm3。

结论

我们的数据显示,GKS 治疗垂体腺瘤后,新的激素缺乏症的发生率与剂量有关。在计划制定过程中,可以使用所概述的安全剂量-体积值来降低发生垂体功能减退的风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验